title: Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study.
abstract: Although the heterogeneity of the therapeutic response to TNF-α blockers seems to be mainly due to genetic factors, several studies showed that a range of factors may influence it. The aim of our study was to investigate the impact of patients' demographic and clinical characteristics on primary response to an anti-TNF-α therapy in psoriatic patients. We retrospectively examined the relationship between various clinical and demographic features and response to treatment with etanercept, adalimumab, and infliximab, evaluated as PASI75 and average PASI improvement at weeks 12, 16, and 14, respectively. We analyzed data obtained from 199 patients. A better response to the treatment was significantly associated with male gender (OR = 2.59), coexistence of psoriatic arthritis (OR = 1.97), and PASI ≤15 at baseline (OR = 0.91). The present study supports that some clinical factors may be potential predictors of response to anti-TNF-α agents in psoriatic patients.
authors.affiliation: Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy.
authors.forename: Clara
authors.initials: C
authors.lastname: De Simone
authors.affiliation: Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy. giacomocaldarola@libero.it.
authors.forename: Giacomo
authors.initials: G
authors.lastname: Caldarola
authors.affiliation: Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy.
authors.forename: Alessia
authors.initials: A
authors.lastname: Maiorino
authors.affiliation: Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Tassone
authors.affiliation: Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy.
authors.forename: Irene
authors.initials: I
authors.lastname: Campana
authors.affiliation: Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy.
authors.forename: Pietro
authors.initials: P
authors.lastname: Sollena
authors.affiliation: Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy.
authors.forename: Ketty
authors.initials: K
authors.lastname: Peris
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D013997:Time Factors; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D001688:Biological Products; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept
keywords: anti-TNF-α; psoriasis; response